Paul Conyngham Launches Gamgee for Dog Cancer Vaccines, Citing 75% Tumor Reduction
Updated
Updated · The Verge · Aug 12
Paul Conyngham Launches Gamgee for Dog Cancer Vaccines, Citing 75% Tumor Reduction
2 articles · Updated · The Verge · Aug 12
Summary
Gamgee has launched to sell personalized mRNA cancer vaccines for dogs, built around Paul Conyngham’s account that an AI-assisted treatment shrank tumors in his dog Rosie.
Aimed first at Australia, the startup says it is recruiting for initial clinical trials, promises a vaccine in about four weeks, and says the process needs less than 20 minutes of veterinarian time.
Its pitch leans on a roughly 75% tumor reduction in a “first documented case,” but the company says that timeline and result come from a single case and costs are not disclosed.
Researchers previously said Rosie’s treatment made it impossible to isolate the vaccine’s effect because it was given alongside another therapy, and the exact role of AI was unclear.
Backed by Y Combinator, Gamgee says it is working with the University of Queensland and UNSW institutes and ultimately wants to expand from pets to personalized human treatments.